This is the first podcast in a series produced with MPR, a product development firm that thrives on creating breakthrough products. Thanks for listening and we hope you enjoy this interview with physician-entrepreneur Dr. Iyad Saidi.
The story of Spirox and its bioresorbable nasal implant is one of great success – the company sold to Entellus for $81 million in July of 2017. And six months later, Entellus was bought by Stryker for $664 million.
But when Spirox co-founder Dr. Iyad Saidi first began developing his nasal device, challenges were abundant. In this interview with MassMedic president Brian Johnson, Saidi tells him that he began raising money to fund his product development efforts in 2008. Facing a devastated economy and an undefined market for his product, Saidi was left wondering how his device would ever make it to patients.
“I was always questioning what I was doing,” Saidi said. ” But I felt confident in the potential and that’s why I invested a lot of my time and money in the initial stages.”
“In working with these physician-entrepreneurs, you start to see some qualities that they share. In this case, it’s the tenacity, it’s being a pragmatist and it’s being a tireless innovator,” says Jeff Champagne, director of business development at MPR.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.